← Back to Search

Ianalumab for Lupus (SIRIUS-SLE 1 Trial)

Phase 3
Recruiting
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 36 to week 60
Awards & highlights
Pivotal Trial

Summary

This trial tests if two new treatments for systemic lupus erythematosus (SLE) are safe, effective & tolerable when given as monthly or quarterly injections.

Who is the study for?
Adults and children aged 12+ (18+ in some regions) diagnosed with systemic lupus erythematosus for at least 6 months, meeting specific disease activity criteria. Participants must weigh over 35 kg and be on stable lupus medications. Excluded are those with certain other health conditions, women who could get pregnant not using effective contraception, recent recipients of live vaccines or certain treatments, and individuals with severe organ dysfunction or infections.
What is being tested?
The trial is testing the effectiveness of Ianalumab against a placebo when given monthly or quarterly as an injection alongside standard lupus treatments. It aims to see if Ianalumab can better control lupus symptoms compared to the usual treatment alone.
What are the potential side effects?
Potential side effects may include reactions at the injection site, increased risk of infections due to immune system alteration by Ianalumab, possible blood disorders, fatigue, and possibly other unknown risks that often come with new immunomodulating drugs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 36 to week 60
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 36 to week 60 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of participants on monthly ianalumab achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4)
Secondary study objectives
Ianalumab concentration in serum during the treatment and follow-up
Number of participants with adverse events
Proportion of participants on monthly or quarterly ianalumab achieving BILAG-based Composite Lupus Assessment (BICLA)
+10 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Ianalumab s.c. quarterlyExperimental Treatment1 Intervention
Ianalumab s.c. quarterly
Group II: Ianalumab s.c. monthlyExperimental Treatment1 Intervention
Ianalumab s.c. monthly
Group III: Placebo s.c. monthlyPlacebo Group1 Intervention
placebo s.c. monthly

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,912 Previous Clinical Trials
4,252,297 Total Patients Enrolled

Media Library

Ianalumab s.c. monthly Clinical Trial Eligibility Overview. Trial Name: NCT05639114 — Phase 3
Lupus Research Study Groups: Ianalumab s.c. monthly, Ianalumab s.c. quarterly, Placebo s.c. monthly
Lupus Clinical Trial 2023: Ianalumab s.c. monthly Highlights & Side Effects. Trial Name: NCT05639114 — Phase 3
Ianalumab s.c. monthly 2023 Treatment Timeline for Medical Study. Trial Name: NCT05639114 — Phase 3
~221 spots leftby Jan 2027